PTC Therapeutics (PTCT) Projected to Release Earnings on Thursday

Key Points

• PTC Therapeutics is expected to report Q3 2026 earnings after market close on October 29. Analysts forecast earnings of $0.2071 per share on revenue of $304.60 million.
• The company’s previous quarter significantly exceeded expectations, reporting $0.92 EPS versus the $0.24 consensus and $360.52 million in revenue, up 101.5% year over year.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $94.93, compared with the stock’s recent price of $62.62; insiders have sold 77,370 shares worth $5.32 million over the past three months.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect PTC Therapeutics to post earnings of $0.2071 per share and revenue of $304.60 million for the quarter. Interested persons can check the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.24 by $0.68. The business had revenue of $360.52 million during the quarter, compared to analyst estimates of $298.63 million. During the same period last year, the company earned ($0.83) earnings per share. The business's revenue for the quarter was up 101.5% compared to the same quarter last year. On average, analysts expect PTC Therapeutics to post $1.19 EPS for the current fiscal year and $1.90 EPS for the next fiscal year.

PTC Therapeutics Price Performance

PTCT stock opened at $62.62 on Thursday. PTC Therapeutics has a twelve month low of $58.80 and a twelve month high of $90.87. The company's 50 day moving average is $66.73 and its two-hundred day moving average is $71.65.

Analysts Set New Price Targets

PTCT has been the subject of several research analyst reports. Barclays upped their target price on shares of PTC Therapeutics from $120.00 to $122.00 and gave the company an "overweight" rating in a report on Friday, August 14th. Royal Bank Of Canada cut their price target on shares of PTC Therapeutics from $85.00 to $75.00 and set a "sector perform" rating on the stock in a research note on Wednesday, October 7th. Raymond James Financial set a $106.00 price target on shares of PTC Therapeutics in a research report on Tuesday. Cantor Fitzgerald upped their price objective on shares of PTC Therapeutics from $130.00 to $137.00 and gave the company an "overweight" rating in a research note on Tuesday, September 22nd. Finally, UBS Group restated a "buy" rating and issued a $90.00 price objective (up from $80.00) on shares of PTC Therapeutics in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, PTC Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $94.93.

Insider Buying and Selling

In related news, VP Mark Boulding sold 435 shares of the stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $64.16, for a total transaction of $27,909.60. Following the completion of the sale, the vice president directly owned 105,272 shares of the company's stock, valued at $6,754,251.52. This trade represents a 0.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Glenn Steele, Jr. sold 12,000 shares of PTC Therapeutics stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $65.16, for a total transaction of $781,920.00. Following the completion of the transaction, the director owned 22,500 shares in the company, valued at approximately $1,466,100. This trade represents a 34.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 77,370 shares of company stock valued at $5,322,261 over the last three months. 5.30% of the stock is currently owned by company insiders.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company's commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.